After being replaced with tyrosine kinase inhibitors like imatinib, interest in IFNα-based therapy has recently reemerged for treatment of chronic myeloid leukemia (CML) [reviewed in reference (241)]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.